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cal models of mammalian ventricular cells (dynamic Luo Rudy formulation) and early 
(myoblast) and late (myofiber) differentiated skeletal cells. The strands were either 
homogenous, or of mixed (half/half) cardiac and skeletal myofiber forms. They were used 
to explore coupling requirements and effects of action potential morphology on ventricu- 
lar-sketstal interaction. 
RESULTS: The action potential duration (APE)) of skeletal cells is short (2.5 ms) and is 
the major limitation of skeletal-to-skeletal and skeletal-to-cardiac excitation. A high 
degree of intercellular coupling was required for skeletal cells to excite their downstream 
neighbors quickly enough, within 2.5 ms, prior to there own repoladzation. The cardiac 
APD is long (178 ms) and there was a long length of time for cardiac cells to charge their 
downstream neighbor, before the charging cell repoladzes. Decreasing intercellular cou- 
pling increased the time necessary to charge adjoining cells. The ratio of intercellular 
coupling reduction to still allow cell-to-cell excitation in homogeneous trands was 45:5:1 
for the ventricular, skeletal myoblast, and skeletal myofiber cell types, respectively. In 
mixed strands, the limiting factor in excitation was any instance that the skeletal cell was 
the source cell. 
CONCLUSION: Skeletal cells need a very high degree of coupling to their neighbors and 
to ventricular myocardium for adequate call-to-cell action potential flow. Gene therapy 
based interventions that prolong the skeletal APD such as introducing a slow inward cal- 
cium current, or use of cells with action potentials longer than 3 ms, would decrease this 
coupling requirement. 
1204-145 Compar i son  of  the  Ef fects  of  L is inopr i l  and a Prolyl 4- 
Hydroxylase Inhibitor (FG041) on Left Ventricular 
Function After Acute Myocardial Infarction 
John I. Nwoau, Maurice Bean, David L Geenen, Jay Bagai, Ajanta De, Beth E. Reed, 
Mehdi Nafissi, Mitchell Brenner, Peter M. Buttrick, University of Illinois at Chicago, 
Chicago, Illinois, Fibrogen INC, South San Francisco, California. 
Background: We have previously shown that proly 4- hydroxylase (P4H) inhibition by 
FG041, which specifically inhibits collagen biosynthesis when given after myocardial inf- 
arction (MI) decreases fibrosis, and improves left ventricular function (LVEF) and sur- 
vival. ACE inhibitors decrease fibrosis and produce similar beneficial effects. It is unclear 
if ACE inhibitors and P4H inhibitors will produce similar and complementary effects on LV 
function post MI. Method: Rats who underwent left coronary artery ligation to produce MI 
were randomized to Lisinopril (Lie, n=13, at 15mg/kg QD) and FG041 (P4H, n=13,at 
50mg/kg BID), Lisinopril and FG041 at same dose (LisP4H, n=10) and to vehicle (con, 
n=13). Echo was performed weekly for 4 weeks then biweekly till week 8 using a 15 mHz 
Linear probe, Results: At randomization, LV function and dimensions were similar in aH 
groups. P4H and Lis produced similar improvement in LVEF compared to control (P<0.05 
weeks 2-6, P =NS week 8). Combination therapy produced a more favorable effect on 
LVEF (see figure P<O.05 weeks 2-8 vs. con) and LV diastolic function (mitral inflow veloc- 
ity 0.97m/s vs. 1.34m/s in con, p=0.028). Conclusion: Our data shows that FG041 and 
Lisinopril produced similar improvement in LVEF while combination therapy produced 
greater improvement in LV systolic and diastolic functions. Thus the two agents have 
comparable and complementary effects on LV function post MI. 
500/0 
45% 
40% 
35% 
30% 
25% 
20% 
15% 
Left Ventrlcular EJecUon FracUen 
wk0 wk l  wk2  wk3 wk4 wk6 wk8 
POSTER SESS ION 
1205 Heart Failure: Prognostic Factors 
Tuesday, March 19, 2002, 3:00 p.m.-5:00 p.m. 
Georgia World Congress Center, Hall G 
Presentation Hour: 3:00 p.m.-4:00 p.m. 
1205-137 Atlas: Do Gender Differences Affect Outcome Results? 
Mareo M. Schleman. AstraZeneca LP , Clinical Research, Wayne, Pennsylvania. 
Background: The Assessment of Treatment with Lisinopdl (L) and Survival (ATLAS) trial 
found high dose L (32.5-35 mg) reduced combined endpoint of deaths and hospitaliza- 
tions by 12% (p=0.0002) and trended to a reduction in all cause mortality by 8% 
(p=0.128). Women (n=648) comprised 20% of patient poulation. This retrospective anal- 
ysis examined whether gender differences were present in demography, outcome 
results, or tolerabilty. Methods: A retrospective analysis of ATLAS data base was made 
based on gender and high and low dose L. Descriptive statistics were applied and an 
arbitrary cut off of 10% was used to identify differences. Results: Demography; Women 
had more history of hypertension than men (48% vs 19.4%) and men had more history of 
ischemic heart disease than women (67.5% vs 52%). Baseline systolic BP was higher in 
women (123.1 mmHg vs 119.4 mmHg). El:, NYHA class, DBP, and previous ACE inhibi- 
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tor use were similar in both groups. Outcome results; All cause mortality hazard ratio 
(HR) for L (high dose :low dose) was neutral in women(HR=1.054, p=0.677) but trended 
positively in men (HR=0.891, p=0.053). Total mortality on either L dose in men was 1130 
(45%) compared to 253 (39%) in women. HR for mortality plus hospitalizations was 
favorable in both women and men, HR=0.829, p=0.033 in women and HR=0.899, 
p=0.016 in men. Tolerability; High dose L was generally well tolerated in both men and 
women. Drop outs related to an Adverse Event (AE) occurred in 115 women (17.7%) and 
in 439 men (17.4%) with CHF and dyspnea the most frequently observed AEs (17%- 
28%). Increased cough occurred more frequently in women (high dose 14.8%, low dose 
18.1%) than men (high dose 9.5%, low dose 11.9%) and sudden death was noted more 
frequently in men (high dose 15.1%, low dose 16%) than women (high dose11%, low 
dose 10.3%). Conclusion: High dose L was beneficial in men and women in reducing 
mortality plus hospitalizations. A strong trend (p=0.053) towards reducing mortality bene- 
fit in men was observed but not in women. A larger study in women is needed to defini- 
tively evaluate the response in mortality on high dose L. The overall results of ATLAS 
suggest uptitretion of L is of benefit to both men and women. 
1205-1 38 Prognostic Importance of a Wide QRS Complex in 
Asymptomatic Patients with Depressed Left Ventricular 
Function in Predicting Morta l i ty  
Sunny Srivastava, Amin AI-Ahmad, Munther K. Homoud, Mark S. Link, N.A. Mark Estes, 
III, Marvin A. Konstam, Paul J. Wang, Deed N. Salem, New England Medical Center, 
Boston, Massachusetts. 
Background: A wide QRS complex in patients with clinical heart failure is a potent predic- 
tor of death. However, the prognostic value of a wide QRS complex in asymptomatic 
patients with depressed left ventricular function is not known. 
Methods: We performed a retrospective analysis on the 4228 patients enrolled in the 
Studies of Left Ventdcular Dysfunction Prevention Trial. All patients had a left ventricutar 
ejection fraction (LVEF) < 35% (mean 28.3%). The mean follow up was 32+/-15 months. 
QRS duration was noted to be > 120ms in 1186 patients and < 120ms in 2292 patients 
upon enrollment into the trial, A QRS duration > 120ms was evaluated as a predictor of 
all cause mortality univariata analysis with a Log-rank statistic. A Cox regression model 
was constructed for multivariate analysis with covariates that included LVEF, age, medi- 
cation and medical history. 
Results: A QRS duration > 120ms was not associated with an increased risk of death 
(univadate p = 0.3t, multivariate p = 0.46). 
Conclusions: In contrast o patients with clinical heart failure, in patients with asymptom- 
atic left ventricular dysfunction QRS duration does not appear to be a predictor for mor- 
tality. 
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1205-140 impact of South Asian (SA) Ethnicity On Presentation 
and Outcomes Following Hospitalization for Congestive 
Heart Fai lure (CHF) 
Narendra Sinoh, Milan Gupta, Tuhina Biswas, Quak M. Nguyen, Rouge Valley Health 
System-CHC site, Toronto, Ontario, Canada, William Osier Health Centre-Brampton 
campus, Brampton, Ontario, Canada. 
SA develop CAD at a younger age and have larger Ml's compared to European Canadi- 
ans (EU). We hypothesized that SA would therefore also develop CHF at a younger age. 
A retrospective review of 887 consecutive pts admitted between 1997-99 to 2 large com- 
munity hospitals with a primary diagnosis of CHF was performed. 
Results: CAD was the primary etiology of CHF in both groups (49 vs 48%). Pts with car- 
diac enzymes > 2 times normal were excluded. 99 (11%) of pts were SA and 728 (79%) 
were EU based on name analysis. 51% were males. SA were much younger (69.1 vs 
75.1yrs, p=.000017), had more diabetes (57 vs 39% p<,001), were less likely smokers 
(24% vs 41% p<.01 ) had lower body mass index (24.4 vs 26.7kg/m2, p=.003), but similar 
hypercholesterolemia (27 vs 22%), hypertension (62 vs 59%), and family history of CAD 
(10 vs 9%). Prior history of CHF was similar in both groups (57 vs 58%) with the average 
ejection fraction also being similar (40 vs 42%). 
On presentation, HR (98.1vs95.7 bpm p=0.4) and BP (139/82 vs 138/77, p=.02) trended 
higher in SA. Serum sodium was lower (135 vs 137mmol, p=,0002). Initial (150 vs 
135mmol, p=0.1) and discharge creatinine (172 vs 144mmol, p=.014) were higher in SA. 
Most in-hospital complication rates were similar but SA had more ventdcular arrhythmias/ 
cardiac arrest (10 vs 5%, p<.05) and less afib (15 vs 24% p<.05). Unadjusted mortality 
was similar (6 vs 11%, p=ns). Evidence-based drug therapies were used with similar fre- 
quency. Overall 66% received ACEVARB, 84% diuretic, 20% beta blockers, 17% 
spironolactone and 11% statins. 
Conclusion Substantial differences at presentation are seen in SA pts hospitalized for 
